Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$0.5 - $1.23 $19,079 - $46,934
-38,158 Reduced 47.15%
42,765 $26,000
Q3 2022

Nov 14, 2022

BUY
$1.1 - $4.19 $89,015 - $339,067
80,923 New
80,923 $89,000

Others Institutions Holding KZIA

About KAZIA THERAPEUTICS LTD


  • Ticker KZIA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,111,300
  • Market Cap $87.5M
  • Description
  • Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...
More about KZIA
Track This Portfolio

Track Old Mission Capital LLC Portfolio

Follow Old Mission Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Old Mission Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Old Mission Capital LLC with notifications on news.